JLPC(600513) Shang Hai Zheng Quan Bao·2025-05-21 19:08Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. held its 2024 annual performance briefing on May 21, 2025, to discuss financial status, development strategy, and corporate governance with investors [1] Group 1: Industry Performance - In 2024, the pharmaceutical manufacturing industry achieved a total revenue of 25,298.5 billion yuan, with a year-on-year change of 0.0% [2] - The industry's total operating costs were 14,729.6 billion yuan, reflecting a year-on-year increase of 2.0% [2] - The total profit for the industry was 3,420.7 billion yuan, showing a year-on-year decline of 1.1% [2] Group 2: Company Financials - The company reported an annual revenue of 2.16 billion yuan, with an operating profit of 131 million yuan and a net profit attributable to shareholders of 84 million yuan [2] - In Q1 2025, the net profit attributable to shareholders was approximately 23.06 million yuan [2] Group 3: Reasons for Profit Decline - The decline in net profit for 2024 was primarily due to a significant increase in R&D investment, reduced investment income, and rising operating expenses influenced by changes in medical insurance policies and market demand [2][4] Group 4: Future Growth Points - The company plans to enhance new drug research and technological innovation, with R&D investment reaching 277 million yuan in 2024, a year-on-year increase of 95.93% [2] - The company has made breakthroughs in innovative R&D, including the advancement of a new drug LH-1801 into phase III clinical trials and the approval of multiple generic drug production licenses [2][4] Group 5: Market and Investor Relations - The company emphasizes value management and investor relations, maintaining a consistent annual dividend payout ratio of 30% [5] - The company is committed to improving its image and enhancing communication with investors through various initiatives [5] Group 6: Regulatory Issues - The company is addressing a recent antitrust penalty by implementing corrective measures and has submitted an application for an administrative penalty hearing [4][5]